Modern express (journalist high) lymphoma is one of the top ten high tumours. On 31 august, the first case of lymphoma treated using car-t cells in the country was successfully discharged, opening new avenues for future treatment of lymphoma。
Mr. Chen, a patient with a massive b-cell lymphoma, received multiple chemotherapy treatments after the onset of the disease in october 2010, but with poor results. Modern express journalists have learned that lymphoma, as a malignant blood tumor, is most prevalent in large b cell lymphoma. The average total life expectancy of the terminally ill is only six months, and only a small number of patients are able to live without disease for a long time. At present, patients receiving multiline therapy have poor prognosis and nearly half of them have lost their treatment response or relapse shortly after transplantation。
In june of this year, mr. Chen received new cytological immunotherapy technologies, car-t, at hospital no. 1 attached to suzhou university, and physical indicators were normal. “car-t-cell biotherapeutic technologies differ from traditional chemotherapy and blood stem cell transplants, are more accurate in terms of tumour cells and significantly reduce the toxic side effects while improving the efficacy of treatment.” the car-t treatment method is described as the extraction of t-cells from the outside of the patient, followed by the application of genetically modified techniques, the preparation of a specific target point for cd19 on the surface of the large b-cell lymphoma cell, the preparation of a specific attack on the corresponding t-cell, and the subsequent transmission of these “reequipped” t-cells back into the patient's body so that they can be accurately identified and eliminated。
Mr. Tung's condition has been assessed as almost completely abating and has been successfully discharged from hospital and is in the process of rehabilitation。
It is known that in june this year the country's first car-t cell therapy drug was approved. Currently, the country has a global lead in the number of research related to the treatment of car-t, and there is a growing knowledge of the treatment of car-t cells. Professor lee zhongxia, the chief of blood medicine at hospital no. 1 of the university of suzhou, is looking forward to this treatment, saying, “car-t-cell therapy not only improves the lives of patients, but also offers hope of healing, and for our doctors and nurses the application of the most advanced technology available at car-t-cell. We shall continue to explore and develop in this field for the benefit of more patients.”
